Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases

Rhea, Elizabeth M.; Babin, Alice; Thomas, Peter; Omer, Mohamed; Weaver, Riley; Hansen, Kim; Banks, William A.; Talbot, Konrad

doi:10.1080/21688370.2023.2292461

Title: Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases

Journal Article · 13 December 2023 · Tissue Barriers

DOI: https://doi.org/10.1080/21688370.2023.2292461 · OSTI ID:2229944

Rhea, Elizabeth M. ^[1]; Babin, Alice ^[2]; Thomas, Peter ^[2]; Omer, Mohamed ^[2]; Weaver, Riley ^[2]; Hansen, Kim ^[2]; Banks, William A. ^[1]; Talbot, Konrad ^[3]

Veterans Affairs Puget Sound Health Care System, Geriatrics Research Education and Clinical Center, Seattle, WA, USA, Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
Veterans Affairs Puget Sound Health Care System, Geriatrics Research Education and Clinical Center, Seattle, WA, USA
Departments of Neurosurgery, Pathology and Human Anatomy, and Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA

Not Available

View Journal Article

Cite

Export

Save

Sponsoring Organization:: USDOE Office of Electricity (OE), Advanced Grid Research & Development. Power Systems Engineering Research

OSTI ID:: 2229944

Journal Information:: Tissue Barriers, Journal Name: Tissue Barriers Journal Issue: 4 Vol. 12; ISSN 2168-8370

Publisher:: Informa UK LimitedCopyright Statement

Country of Publication:: Country unknown/Code not available

Language:: English

References (78)

Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline Spinelli, Matteo; Fusco, Salvatore; Grassi, Claudio Frontiers in Neuroscience, Vol. 13 https://doi.org/10.3389/fnins.2019.00788	journal	July 2019
Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions Lee, Jung Hyun; Jahrling, Jordan B.; Denner, Larry Journal of Alzheimer's Disease, Vol. 64, Issue s1 https://doi.org/10.3233/JAD-179923	journal	June 2018
Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain? Banks, William Current Pharmaceutical Design, Vol. 10, Issue 12 https://doi.org/10.2174/1381612043384862	journal	May 2004
Labeling of proteins by reductive methylation using sodium cyanoborohydride. Jentoft, N.; Dearborn, D. G. Journal of Biological Chemistry, Vol. 254, Issue 11 https://doi.org/10.1016/S0021-9258(17)30016-9	journal	June 1979
Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist Naver, Signe V.; Jimenez-Solem, Espen; Christensen, Mikkel Clinical Investigation, Vol. 4, Issue 8 https://doi.org/10.4155/cli.14.65	journal	August 2014
A Pilot Study of Exenatide Actions in Alzheimer’s Disease Mullins, Roger J.; Mustapic, Maja; Chia, Chee W. Current Alzheimer Research, Vol. 16, Issue 8 https://doi.org/10.2174/1567205016666190913155950	journal	October 2019
Serum Proteins Bypass the Blood-Brain Fluid Barriers for Extracellular Entry to the Central Nervous System Broadwell, Richard D.; Sofroniew, Michael V. Experimental Neurology, Vol. 120, Issue 2 https://doi.org/10.1006/exnr.1993.1059	journal	April 1993
Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline Talbot, Konrad; Wang, Hoau-Yan; Kazi, Hala Journal of Clinical Investigation, Vol. 122, Issue 4 https://doi.org/10.1172/JCI59903	journal	April 2012
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists Novikoff, Aaron; O'Brien, Shannon L.; Bernecker, Miriam Molecular Metabolism, Vol. 49 https://doi.org/10.1016/j.molmet.2021.101181	journal	July 2021
Species Differences in Pharmacokinetics and Pharmacodynamics Toutain, Pierre-Louis; Ferran, Aude; Bousquet-Mélou, Alain Comparative and Veterinary Pharmacology https://doi.org/10.1007/978-3-642-10324-7_2	book	January 2010
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease Nowell, Joseph; Blunt, Eleanor; Edison, Paul Molecular Psychiatry, Vol. 28, Issue 1 https://doi.org/10.1038/s41380-022-01792-4	journal	October 2022
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist Willard, Francis S.; Douros, Jonathan D.; Gabe, Maria B. N. JCI Insight, Vol. 5, Issue 17 https://doi.org/10.1172/jci.insight.140532	journal	September 2020
Insulin resistance in Alzheimer's disease Diehl, Thomas; Mullins, Roger; Kapogiannis, Dimitrios Translational Research, Vol. 183 https://doi.org/10.1016/j.trsl.2016.12.005	journal	May 2017
Transport of α-Aminoisobutyric Acid across Brain Capillary and Cellular Membranes Blasberg, Ronald G.; Fenstermacher, Joseph D.; Patlak, Clifford S. Journal of Cerebral Blood Flow & Metabolism, Vol. 3, Issue 1 https://doi.org/10.1038/jcbfm.1983.2	journal	March 1983
Trial of Cinpanemab in Early Parkinson’s Disease Lang, Anthony E.; Siderowf, Andrew D.; Macklin, Eric A. New England Journal of Medicine, Vol. 387, Issue 5 https://doi.org/10.1056/NEJMoa2203395	journal	August 2022
Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS Akimoto, Hayato; Negishi, Akio; Oshima, Shinji American Journal of Alzheimer's Disease & Other Dementiasr, Vol. 35 https://doi.org/10.1177/1533317519899546	journal	January 2020
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers Nørgaard, Caroline Holm; Friedrich, Sarah; Hansen, Charlotte Thim Alzheimer's & Dementia: Translational Research & Clinical Interventions, Vol. 8, Issue 1 https://doi.org/10.1002/trc2.12268	journal	January 2022
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke Reish, Nicholas J.; Jamshidi, Pouya; Stamm, Brian New England Journal of Medicine, Vol. 388, Issue 5 https://doi.org/10.1056/NEJMc2215148	journal	February 2023
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review Reich, Niklas; Hölscher, Christian Frontiers in Neuroscience, Vol. 16 https://doi.org/10.3389/fnins.2022.970925	journal	September 2022
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data Patlak, Clifford S.; Blasberg, Ronald G.; Fenstermacher, Joseph D. Journal of Cerebral Blood Flow & Metabolism, Vol. 3, Issue 1 https://doi.org/10.1038/jcbfm.1983.1	journal	March 1983
Semaglutide lowers body weight in rodents via distributed neural pathways Gabery, Sanaz; Salinas, Casper G.; Paulsen, Sarah J. JCI Insight, Vol. 5, Issue 6 https://doi.org/10.1172/jci.insight.133429	journal	March 2020
FDA approves Alzheimer’s drug lecanemab amid safety concerns Reardon, Sara Nature, Vol. 613, Issue 7943 https://doi.org/10.1038/d41586-023-00030-3	journal	January 2023
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease Yang, Xiaoyan; Feng, Peng; Ji, Rong Expert Opinion on Therapeutic Targets, Vol. 26, Issue 5 https://doi.org/10.1080/14728222.2022.2079492	journal	May 2022
Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches Kellar, Derek; Craft, Suzanne The Lancet Neurology, Vol. 19, Issue 9 https://doi.org/10.1016/S1474-4422(20)30231-3	journal	September 2020
Permeability of the Blood-Brain Barrier to Albumin and Insulin in the Young and Aged SAMP8 Mouse Banks, W. A.; Farr, S. A.; Morley, J. E. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, Vol. 55, Issue 12 https://doi.org/10.1093/gerona/55.12.B601	journal	December 2000
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases Hölscher, Christian Frontiers in Synaptic Neuroscience, Vol. 14 https://doi.org/10.3389/fnsyn.2022.955258	journal	July 2022
Cerebrovascular insulin receptors are defective in Alzheimer’s disease Leclerc, Manon; Bourassa, Philippe; Tremblay, Cyntia Brain, Vol. 146, Issue 1 https://doi.org/10.1093/brain/awac309	journal	October 2022
An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex Zhang, Y.; Chen, K.; Sloan, S. A. Journal of Neuroscience, Vol. 34, Issue 36 https://doi.org/10.1523/JNEUROSCI.1860-14.2014	journal	September 2014
Insulin resistance in the nervous system Kim, Bhumsoo; Feldman, Eva L. Trends in Endocrinology & Metabolism, Vol. 23, Issue 3 https://doi.org/10.1016/j.tem.2011.12.004	journal	March 2012
Ghrelin transport across the blood–brain barrier can occur independently of the growth hormone secretagogue receptor Rhea, Elizabeth M.; Salameh, Therese S.; Gray, Sarah Molecular Metabolism, Vol. 18 https://doi.org/10.1016/j.molmet.2018.09.007	journal	December 2018
Insulin regulates P-glycoprotein in rat brain microvessel endothelial cells via an insulin receptor-mediated PKC/NF-κB pathway but not a PI3K/Akt pathway Liu, Haiyan; Yang, Huiwen; Wang, Dianlei European Journal of Pharmacology, Vol. 602, Issue 2-3 https://doi.org/10.1016/j.ejphar.2008.11.026	journal	January 2009
Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1 Liu, Xiao‐Yu; Zhang, Ni; Zhang, Sheng‐Xiao European Journal of Neuroscience, Vol. 54, Issue 10 https://doi.org/10.1111/ejn.15502	journal	November 2021
Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Hölscher, Christian Neuropharmacology, Vol. 136 https://doi.org/10.1016/j.neuropharm.2018.01.040	journal	July 2018
Progress towards therapies for disease modification in Parkinson's disease Vijiaratnam, Nirosen; Simuni, Tanya; Bandmann, Oliver The Lancet Neurology, Vol. 20, Issue 7 https://doi.org/10.1016/S1474-4422(21)00061-2	journal	July 2021
Brain insulin resistance: role in neurodegenerative disease and potential for targeting Hölscher, Christian Expert Opinion on Investigational Drugs, Vol. 29, Issue 4 https://doi.org/10.1080/13543784.2020.1738383	journal	March 2020
Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer’s disease Wakabayashi, Tomoko; Yamaguchi, Kazuki; Matsui, Kentaro Molecular Neurodegeneration, Vol. 14, Issue 1 https://doi.org/10.1186/s13024-019-0315-7	journal	April 2019
Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease Velazquez, Ramon; Tran, An; Ishimwe, Egide Neurobiology of Aging, Vol. 58 https://doi.org/10.1016/j.neurobiolaging.2017.06.003	journal	October 2017
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Frias, Juan Pablo; Bastyr, Edward J.; Vignati, Louis Cell Metabolism, Vol. 26, Issue 2 https://doi.org/10.1016/j.cmet.2017.07.011	journal	August 2017
Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies Filippi, Massimo; Cecchetti, Giordano; Spinelli, Edoardo Gioele JAMA Neurology, Vol. 79, Issue 3 https://doi.org/10.1001/jamaneurol.2021.5205	journal	March 2022
Soluble Interleukin-6 Receptor Induces Motor Stereotypies and Co-Localizes with Gp130 in Regions Linked to Cortico-Striato-Thalamo-Cortical Circuits Patel, Ankur; Zhu, Youhua; Kuzhikandathil, Eldo V. PLoS ONE, Vol. 7, Issue 7 https://doi.org/10.1371/journal.pone.0041623	journal	July 2012
Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats Lee, Tae Suk; Park, Eun Ji; Choi, Minkyu Journal of Chromatography B, Vol. 1221 https://doi.org/10.1016/j.jchromb.2023.123688	journal	April 2023
High fat diet induces brain insulin resistance and cognitive impairment in mice Kothari, Vishal; Luo, Yuwen; Tornabene, Talia Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Vol. 1863, Issue 2 https://doi.org/10.1016/j.bbadis.2016.10.006	journal	February 2017
Novel targeted therapies for Parkinson’s disease Ntetsika, Theodora; Papathoma, Paraskevi-Evita; Markaki, Ioanna Molecular Medicine, Vol. 27, Issue 1 https://doi.org/10.1186/s10020-021-00279-2	journal	February 2021
GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models Zhang, Zhen Qiang; Hölscher, Christian Peptides, Vol. 125 https://doi.org/10.1016/j.peptides.2019.170184	journal	March 2020
Alzheimer's disease: Recent treatment strategies Vaz, Miguel; Silvestre, Samuel European Journal of Pharmacology, Vol. 887 https://doi.org/10.1016/j.ejphar.2020.173554	journal	November 2020
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun, Tamer; Sloop, Kyle W.; Loghin, Corina Molecular Metabolism, Vol. 18 https://doi.org/10.1016/j.molmet.2018.09.009	journal	December 2018
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs Alves, Francesca; Kalinowski, Pawel; Ayton, Scott Neurology, Vol. 100, Issue 20 https://doi.org/10.1212/WNL.0000000000207156	journal	May 2023
Differential Permeability of the Blood–Brain Barrier to Two Pancreatic Peptides: Insulin and Amylin Banks, William A.; Kastin, Abba J. Peptides, Vol. 19, Issue 5 https://doi.org/10.1016/S0196-9781(98)00018-7	journal	May 1998
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Kuritzky, Louis; Umpierrez, Guillermo; Ekoé, Jean Marie Postgraduate Medicine, Vol. 126, Issue 6 https://doi.org/10.3810/pgm.2014.10.2821	journal	October 2014
Insulin in the Brain: Its Pathophysiological Implications for States Related with Central Insulin Resistance, Type 2 Diabetes and Alzheimerâ€™s Disease BlÃ¡zquez, Enrique; VelÃ¡zquez, Esther; Hurtado-Carneiro, VerÃ³nica Frontiers in Endocrinology, Vol. 5 https://doi.org/10.3389/fendo.2014.00161	journal	October 2014
Lecanemab in Early Alzheimer’s Disease van Dyck, Christopher H.; Swanson, Chad J.; Aisen, Paul New England Journal of Medicine, Vol. 388, Issue 1 https://doi.org/10.1056/NEJMoa2212948	journal	January 2023
Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey Balin, Brian J.; Broadwell, Richard D.; Salcman, Michael Journal of Comparative Neurology, Vol. 251, Issue 2 https://doi.org/10.1002/cne.902510209	journal	September 1986
GLP-1R Signaling and Functional Molecules in Incretin Therapy Wan, Wenwei; Qin, Qikai; Xie, Linshan Molecules, Vol. 28, Issue 2 https://doi.org/10.3390/molecules28020751	journal	January 2023
The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease Maskery, Mark; Goulding, Elizabeth Mary; Gengler, Simon American Journal of Alzheimer's Disease & Other Dementiasr, Vol. 35 https://doi.org/10.1177/1533317520953041	journal	January 2020
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs Katsenos, Andreas P.; Davri, Athena S.; Simos, Yannis V. Expert Opinion on Investigational Drugs, Vol. 31, Issue 1 https://doi.org/10.1080/13543784.2022.2022122	journal	January 2022
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans Finan, B.; Ma, T.; Ottaway, N. Science Translational Medicine, Vol. 5, Issue 209 https://doi.org/10.1126/scitranslmed.3007218	journal	October 2013
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors Zhao, Fenghui; Zhou, Qingtong; Cong, Zhaotong Nature Communications, Vol. 13, Issue 1 https://doi.org/10.1038/s41467-022-28683-0	journal	February 2022
Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes Cheang, Jia Ying; Moyle, Peter M. ChemMedChem, Vol. 13, Issue 7 https://doi.org/10.1002/cmdc.201700781	journal	February 2018
Albiglutide: a unique GLP-1 receptor agonist Rendell, Marc S. Expert Opinion on Biological Therapy, Vol. 16, Issue 12 https://doi.org/10.1080/14712598.2016.1240780	journal	October 2016
A TfR-Binding Cystine-Dense Peptide Promotes Blood–Brain Barrier Penetration of Bioactive Molecules Crook, Zachary R.; Girard, Emily; Sevilla, Gregory P. Journal of Molecular Biology, Vol. 432, Issue 14 https://doi.org/10.1016/j.jmb.2020.04.002	journal	June 2020
Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial (P9-11.005) Malatt, Camille; Wu, Tina; Bresee, Catherine Neurology, Vol. 98, Issue 18_supplement https://doi.org/10.1212/WNL.98.18_supplement.3068	journal	May 2022
Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites Rhea, Elizabeth M.; Banks, William A.; Raber, Jacob Biomedicines, Vol. 10, Issue 7 https://doi.org/10.3390/biomedicines10071582	journal	July 2022
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review Yu, Tien-Wei; Lane, Hsien-Yuan; Lin, Chieh-Hsin International Journal of Molecular Sciences, Vol. 22, Issue 15 https://doi.org/10.3390/ijms22158208	journal	July 2021
Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease Miziak, Barbara; Błaszczyk, Barbara; Czuczwar, Stanisław J. Pharmaceuticals, Vol. 14, Issue 5 https://doi.org/10.3390/ph14050458	journal	May 2021
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease Glotfelty, Elliot J.; Olson, Lars; Karlsson, Tobias E. Expert Opinion on Investigational Drugs, Vol. 29, Issue 6 https://doi.org/10.1080/13543784.2020.1764534	journal	May 2020
Insulin action on brain microvessels; Effect on alkaline phosphatase Catalán, R. E.; Martínez, A. M.; Aragonés, M. D. Biochemical and Biophysical Research Communications, Vol. 150, Issue 2 https://doi.org/10.1016/0006-291X(88)90433-0	journal	January 1988
Impaired brain insulin signalling in Parkinson's disease Bassil, Fares; Delamarre, Anna; Canron, Marie‐Hélène Neuropathology and Applied Neurobiology, Vol. 48, Issue 1 https://doi.org/10.1111/nan.12760	journal	September 2021
Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice Ong, Qi-Rui; Chan, Elizabeth S.; Lim, Mei-Li Scientific Reports, Vol. 4, Issue 1 https://doi.org/10.1038/srep03754	journal	January 2014
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art Nauck, Michael A.; Quast, Daniel R.; Wefers, Jakob Molecular Metabolism, Vol. 46 https://doi.org/10.1016/j.molmet.2020.101102	journal	April 2021
Insulin transport across the blood–brain barrier can occur independently of the insulin receptor Rhea, Elizabeth M.; Rask‐Madsen, Christian; Banks, William A. The Journal of Physiology, Vol. 596, Issue 19 https://doi.org/10.1113/JP276149	journal	August 2018
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics Salameh, Therese S.; Rhea, Elizabeth M.; Talbot, Konrad Biochemical Pharmacology, Vol. 180 https://doi.org/10.1016/j.bcp.2020.114187	journal	October 2020
The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases Cheng, Dihe; Yang, Shuo; Zhao, Xue Drug Design, Development and Therapy, Vol. Volume 16 https://doi.org/10.2147/DDDT.S348055	journal	March 2022
Trial of Prasinezumab in Early-Stage Parkinson’s Disease Pagano, Gennaro; Taylor, Kirsten I.; Anzures-Cabrera, Judith New England Journal of Medicine, Vol. 387, Issue 5 https://doi.org/10.1056/NEJMoa2202867	journal	August 2022
Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF Poduslo, Joseph F.; Curran, Geoffrey L. Molecular Brain Research, Vol. 36, Issue 2 https://doi.org/10.1016/0169-328X(95)00250-V	journal	March 1996
Endothelial insulin receptors differentially control insulin signaling kinetics in peripheral tissues and brain of mice Konishi, Masahiro; Sakaguchi, Masaji; Lockhart, Samuel M. Proceedings of the National Academy of Sciences, Vol. 114, Issue 40 https://doi.org/10.1073/pnas.1710625114	journal	September 2017
Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease De Felice, Fernanda G.; Ferreira, Sergio T. Diabetes, Vol. 63, Issue 7 https://doi.org/10.2337/db13-1954	journal	June 2014
Insulin and Insulin Resistance in Alzheimer’s Disease Sędzikowska, Aleksandra; Szablewski, Leszek International Journal of Molecular Sciences, Vol. 22, Issue 18 https://doi.org/10.3390/ijms22189987	journal	September 2021
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review Berlanga-Acosta, Jorge; Guillén-Nieto, Gerardo; Rodríguez-Rodríguez, Nadia Frontiers in Endocrinology, Vol. 11 https://doi.org/10.3389/fendo.2020.560375	journal	November 2020

Similar Records

Reductions in (/sup 3/H)nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study

Journal Article · 1988 · Neurology; (United States) · OSTI ID:7067845

Whitehouse, P J; Martino, A M; Wagster, M V; +4 more

Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients

Journal Article · 1993 · Genomics; (United States) · OSTI ID:7009534

Shoffner, J M; Brown, M D; Torroni, A; +7 more

Acetylcholinesterase inhibitors from southern African plants: An overview of ethnobotanical, pharmacological potential and phytochemical research including and beyond Alzheimer's disease treatment

Journal Article · 2018 · South African Journal of Botany · OSTI ID:1755276

Masondo, N. A.; Stafford, G. I.; Aremu, A. O.; +1 more

Title: Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases

Citation Formats

References (78)

Similar Records

Related Subjects